Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma

NCT00568308 is registered in ClinicalTrials.gov with Progen Pharmaceuticals as lead sponsor.

NCT NCT00568308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00568308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma
Lead sponsor
Progen Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2007
Completion date
July 31, 2008
Enrollment
600 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, hepatocellular carcinoma, hepatoma, liver cancer, primary liver cancer